Beta Drugs Limited Stock Price Today (NSE: BETA)
Fundamental Score
Beta Drugs Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Beta Drugs Limited share price today is ₹1971.00, up +18.40% on NSE/BSE as of 22 October 2026. Beta Drugs Limited (BETA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.19K (Cr). The 52-week high for BETA share price is ₹2550.00 and the 52-week low is ₹1529.00. At a P/E ratio of 61.38x, BETA is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 18.78% and a debt-to-equity ratio of 0.60.
Beta Drugs Limited Share Price Chart — NSE/BSE Historical Performance
Beta Drugs Limited share price chart: -13.65% return over the past month. 52-week high ₹2550.00, 52-week low ₹1529.00.
Beta Drugs Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1664.70 | ₹1997.60 | ₹1616.00 | ₹1971.00 | 5.67L (Cr) | |
| ₹1701.10 | ₹1710.00 | ₹1629.00 | ₹1664.70 | 24.98K (Cr) | |
| ₹1779.80 | ₹1779.80 | ₹1700.00 | ₹1719.60 | 18.55K (Cr) | |
| ₹1786.00 | ₹1804.90 | ₹1713.50 | ₹1783.00 | 26.53K (Cr) | |
| ₹1700.00 | ₹1870.00 | ₹1674.20 | ₹1750.30 | 1.61L (Cr) | |
| ₹1686.00 | ₹1718.90 | ₹1625.00 | ₹1699.50 | 56.68K (Cr) | |
| ₹1845.00 | ₹1859.40 | ₹1660.00 | ₹1677.70 | 1.25L (Cr) | |
| ₹1950.00 | ₹1974.90 | ₹1835.00 | ₹1844.30 | 53.17K (Cr) | |
| ₹1910.00 | ₹1974.00 | ₹1703.10 | ₹1950.20 | 1.59L (Cr) | |
| ₹2000.00 | ₹2000.00 | ₹1890.00 | ₹1898.00 | 24.56K (Cr) |
Beta Drugs Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2030.00 | ₹2173.80 | ₹1616.00 | ₹1971.00 | -2.91% | |
| ₹2277.00 | ₹2285.00 | ₹2002.60 | ₹2053.00 | -9.84% | |
| ₹2525.70 | ₹2550.00 | ₹2153.00 | ₹2259.90 | -10.52% | |
| ₹1815.00 | ₹1815.00 | ₹1529.00 | ₹1661.10 | -8.48% | |
| ₹1820.00 | ₹1895.00 | ₹1783.00 | ₹1871.55 | +2.83% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Beta Drugs Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Beta Drugs Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BETA across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (18.78%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (19.33%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (21.40%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (27.08% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (28.67% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (28.76% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Healthy Liquidity Position (Current Ratio: 3.10)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (58.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 61.38x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (8.96x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Profit Decline Concern (-15.18%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 7.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Beta Drugs Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Beta Drugs Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
56.3/100 | ₹1971.00₹1971 | ₹2191.99₹2191.99 | 61.38Average 61.4 Average | 18.78%Good 18.78% Good | 19.33%Good 19.33% Good | 0.60Good 0.6 Good | 28.76%Excellent 28.76% Excellent | 27.08%Excellent 27.08% Excellent | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 72.9/100 | ₹1758.80₹1759 | ₹421988.88₹421988.88 | 34.90Average 34.9 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 67.2/100 | ₹9144.50₹9145 | ₹242329.25₹242329.25 | 82.97Average 83.0 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 54.8/100 | ₹4558.90₹4559 | ₹154300.53₹154300.53 | 72.83Average 72.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 71.6/100 | ₹1123.00₹1123 | ₹112075.40₹112075.40 | 25.03Average 25.0 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 53.5/100 | ₹2060.10₹2060 | ₹111296.90₹111296.90 | 101.68Average 101.7 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 35.2/100 | ₹1325.10₹1325 | ₹107048.20₹107048.20 | 31.75Average 31.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 36.5/100 | ₹1233.00₹1233 | ₹102955.50₹102955.50 | 31.87Average 31.9 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.90₹1667 | ₹95913.43₹95913.43 | 26.05Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 59.7/100 | ₹2275.50₹2276 | ₹93978.15₹93978.15 | 45.98Average 46.0 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 77.1/100 | ₹1961.60₹1962 | ₹89694.16₹89694.16 | 16.21Average 16.2 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price421988.88 Cr
- Divi's Laboratories Limited share price242329.25 Cr
- Torrent Pharmaceuticals Limited share price154300.53 Cr
- Zydus Lifesciences Limited share price112075.40 Cr
- Laurus Labs Limited share price111296.90 Cr
Beta Drugs Limited PE Ratio History
Historical price-to-earnings ratio for BETA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹36.10 | ₹2009.00 | 55.7x |
| FY 2023 | ₹30.43 | ₹1470.00 | 48.3x |
| FY 2022 | ₹24.59 | ₹710.00 | 28.9x |
| FY 2021 | ₹11.62 | ₹640.25 | 55.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Beta Drugs Limited Quarterly Performance
Latest quarterly metrics for BETA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
0.21%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-15.18%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
27.08%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
28.76%
Compounded annual net profit growth over 5 years
Beta Drugs Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BETA — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Beta Drugs Limited Financial Statements
Annual income statement, balance sheet and cash flow for Beta Drugs Limited (BETA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Beta Drugs Limited
About BETA (Beta Drugs Limited)
Beta Drugs Limited (BETA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current... market capitalisation of ₹2.19K (Cr). Beta Drugs Limited has delivered a Return on Equity (ROE) of 18.78% and a ROCE of 19.33%. The debt-to-equity ratio stands at 0.60, reflecting the company's capital structure. Investors tracking BETA share price can monitor key metrics including P/E ratio, promoter holding of 58.91%, and quarterly earnings growth.
Company Details
BETA Share Price: Frequently Asked Questions
What is the current share price of Beta Drugs Limited?
Beta Drugs Limited (BETA) trades at ₹1971.00 on NSE. Market cap ₹2.19K (Cr). Educational data only.
What is the P/E ratio of Beta Drugs Limited?
Beta Drugs Limited has a P/E of 61.38x vs industry average 34.89x.
What is the Bull Run score for Beta Drugs Limited?
Beta Drugs Limited has a Bull Run score of 56.3/100 based on 25+ financial parameters.
Does Beta Drugs Limited pay dividends?
Beta Drugs Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Beta Drugs Limited?
Beta Drugs Limited has ROE of 18.78%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Beta Drugs Limited?
Beta Drugs Limited has debt-to-equity of 0.60.
Is Beta Drugs Limited a good investment?
Bull Run gives Beta Drugs Limited a score of 56.3/100. This is not investment advice — consult a SEBI-registered advisor.